UCB SA (0NZT)
LSE
Closed
Aug 24, 2026
Day's Range
219.1052 wk Range
190.00Overview - 0NZT - UCB SA
Key Statistics
Valuation
Enterprise Value
16.11B
P/E (Trailing)
‪127.93‬
Price / Sales (TTM)
‪8.65‬
Price / Book
‪4.56‬
EV / EBITDA
‪14.20‬
Profitability
Profit Margin
‪6.45%‬
Operating Margin
‪10.64%‬
Return on Assets
‪2.14%‬
Return on Equity
‪3.69%‬
Ownership
Shares Outstanding
190.36M
Float
120.27M
Held by Insiders
‪38.03%‬
Held by Institutions
‪40.79%‬
Price stats
Beta
‪0.33‬
50-Day Avg
‪239.94‬
200-Day Avg
‪247.94‬
Dividends
Payout Ratio
‪78.23%‬
Frequency
Annual
Market Cap - 0NZT - UCB SA
Peers - 0NZT - UCB SA
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0NZTLSEUCB SA44.92BMarket Cap+9.47%52-week change128.71P/E (Trailing)‪6.45%‬Profit Margin
- 0MGBLSEGenmab A/S173.69BMarket Cap+27.59%52-week change30.65P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated140.34BMarket Cap+29.12%52-week change0.58P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.90.49BMarket Cap+31.55%52-week change0.12P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna, Inc.72.10BMarket Cap+82.56%52-week change55.34P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE52.61BMarket Cap+34.75%52-week change42.42P/E (Trailing)‪-47.51%‬Profit Margin
- 0K91LSENorthern Trust Corporation40.97BMarket Cap+29.60%52-week change0.26P/E (Trailing)‪24.67%‬Profit Margin
Profile Summary - 0NZT - UCB SA
About
UCB SA is a multinational biopharmaceutical company headquartered in Brussels, Belgium, founded in 1928 by Emmanuel Janssen. It specializes in developing innovative medicines for severe neurological and immunological diseases, including epilepsy, Parkinson's disease, Crohn's disease, psoriasis, and autoimmune…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
